关闭
 
读者在线:用户名 密码
首页 期刊简介 投稿须知 期刊目录 专家风采 编委会 特邀顾问 广告发行 联系我们 移动出版
  1. 1
  2. 2
  3. 3
  4. 4
  5. 5



刊物信息
期刊名称:药物分析杂志
主管单位:中国科学技术协会
主办单位:中国药学会
承办:中国食品药品检定研究院
主编:金少鸿
编辑部主任:粟晓黎
地址:北京天坛西里2号
邮政编码:100050
电话:010-67012819,67058427
电子邮箱:ywfx@nicpbp.org.cn
国际标准刊号:ISSN 0254-1793
国内统一刊号:CN 11-2224/R
邮发代号:2-237

 

访问统计
您是第  3 9 8 5 8 4 位浏览者
您当前的位置:首页 >> 正文

抗肿瘤药物吉非替尼的晶型研究进展

Research progress of the crystalline forms study of antitumor drug gefitinib

作者: 陈芊茜 
作者(英文):CHEN Qian-xi
分类号:
出版年·卷·期(页码):2016,36 (10):0-0
DOI: 10.16155/j.0254-1793.2017.01.01
-----摘要:-------------------------------------------------------------------------------------------

本文调研了与吉非替尼晶型有关的大量文献,从晶型种类、晶型制备、晶型表征以及晶型讨论4个方面进行了综述。吉非替尼现已发现有8种晶型,各种晶型物质可通过直接或间接的制备方式来获得,已应用于对这些晶型进行分析表征的技术有单晶X射线衍射分析、粉末X射线衍射分析、差示扫描量热分析、热重分析、红外光谱分析、熔点分析等分析方法。通过对表征结果的比较总结,对吉非替尼多晶型形成原因进行了分析,并在已有研究基础上探讨了选择Form 1成为药用晶型的原因。本文对部分实验结果提出了质疑,指出了现有文献对于吉非替尼多晶型的的研究缺乏系统性,现有研究数据并不完整,特别是缺乏关于吉非替尼各晶型的溶解度、生物学等关键数据。因此,对吉非替尼的多晶型研究还需要更系统更深入。

-----英文摘要:---------------------------------------------------------------------------------------

This article gives a review on the description,preparation,characterization and discussion of crystalline forms based on the literatures. Totally 8 crystalline forms which can be obtained directly or indirectly have been found. The techniques adopted to characterize the polymorphic materials include single crystal X-ray diffraction,powder X-ray diffraction,differential scanning calorimeter,thermogravimetric analysis,infrared spectroscopic analysis and melting point analysis. The reasons of polymorphs formation and choosing Form 1 as predominant crystalline form are dissected by comparing the characterizing results. Some data of the experimental results have been questioned. The article pointed out some remaining problems in the research on gefitinib polymorphs,such as lack of systematicness and incompleteness of experimental data,whic is especially so for the solubility and some other biological data. At length,further study on gefitinib polymorphs developing in the future is indicated.

-----参考文献:---------------------------------------------------------------------------------------
[1] FUKUHARA T,MAEMONDO M,INOUE A,et al. Factors associated with a poor response to gefitinib in the NEJ002 study:Smoking and the L858R mutation[J]. Lung Cancer, 2015,88(2): 181
[2] NISHIO M, HORIIKE A, MURAKAMI H, et al. Phase I study of the HER3-targeted antibody patritumab(U3-1287)combined with erlotinib in Japanese patients with non-small cell lung cancer[J]. Lung Cancer, 2015,88(3): 275
[3] SUGITA S, ITO K, YAMASHIRO Y, et al. EGFR-independent autophagy induction with gefitinib and enhancement of its cytotoxic effect by targeting autophagy with clarithromycin in non-small cell lung cancer cells[J]. Biochem Biophys Res Commun, 2015,461(1): 28
[4] NARITA Y, MATSUSHIMA Y, SHIROIWA T, et al. Costeffectiveness analysis of EGFR mutation testing and gefitinib as first-line therapy for non-small cell lung cancer[J]. Lung Cancer, 2015,90(1): 71
[5] 徐永平,张洋,王宏亮,等. 吉非替尼的合成新工艺研究[J]. 化学通报, 2014, 77(12): 1236 XU YP, ZHANG Y, WANG HL, et al. The research on novel synthetic process of gefitinib[J]. Chemistry, 2014,77(12): 1236
[6] GILDAY JP, GRAHAM AS, YMEN BI, et al. Novel Crystalline Forms of the Anti-cancer Compound ZD1839: Great Britain,WO 03/072108 A1[P].2003-09-04
[7] JYOTHI P,VENKAIAH C. Novel Crystalline Form of Gefitinib and a Process for Its Preparation:India,WO 2006/090413 A1[P].2006-08-31
[8] 彭涛,任武贤,吕立天,等. 抗癌化合物ZD1839的无定形物及其制备方法:中国, CN 103896861 A[P]. 2014-07-02 PENG T, REN WX, LÜ LT, et al. The Amorphous Form of Anticancer Compound ZD1839 and Its Preparation: China, CN 103896861 A[P]. 2014-07-02
[9] 方干,王举波,司永星,等. 一种吉非替尼新晶型及其制备方法: 中国, CN 103910690 A[P]. 2014-07-09 FANG G, WANG JB, SI YX, et al. Novel Crystalline Form of Gefitinib and Its Preparation: China, CN 103910690 A[P]. 2014-07-09
[10] 林栋,冷传新,范传文,等. 吉非替尼乙二醇溶剂合物及其制备方法和用途:中国, CN 104693127 A[P]. 2015-06-10 LIN D, LENG CX, FAN CW, et al. The Glycol Solvate of Gefitinib and Its Preparation and Application:China, CN 104693127 A[P]. 2015-06-10
[11] 沈鑫,廖立新,林复兴,等.一种吉非替尼的制备方法:中国, CN 101463012 B[P].2011-06-08 SHEN X, LIAO LX, LIN FX, et al. A Preparation Method of Gefitinib: China, CN 101463012 B[P].2011-06-08
[12] 吉民,郑友广,李铭东. 一种吉非替尼的制备方法:中国, CN 101148439 B[P].2011-06-22 JI M, ZHENG Y G, LI M D. A Preparation Method of Gefitinib: China, CN 101148439[P].2011-06-22
[13] 赵长阔,刘赟,王先桓. 吉非替尼的制备方法:中国, CN 102153518 B[P].2012-10-10 ZHAO CK, LIU Y, WANG XH. The Preparation Method of Gefitinib: China, CN 102153518 B[P].2012-10-10
[14] 秦凌浩,叶连宝,胡巧红,等.一种吉非替尼的制备方法:中国, CN 102757392 A[P].2012-10-31 QIN LH, YE LB, HU QH, et al. A Preparation Method of Gefitinib: China, CN 102757392 A[P].2012-10-31
[15] 张久彦,严飞飞,张辉,等.一种吉非替尼的制备方法:中国, CN 103304491 A[P].2013-09-18 ZHANG JY, YAN FF, ZHANG H, et al. A Preparation Method of Gefitinib: China, CN 103304491 A[P].2013-09-18
[16] 刘永东,闵涛,车晓明,等. 一种吉非替尼的新杂质及其制备方法:中国, CN 103755648 A[P].2014-04-30 LIU YD, MIN T, CHE XM, et al. A New Impurity of Gefitinib and Its Preparation Method: China, CN 103755648 A[P].2014-04-30
[17] 尚德斌,李能刚.一种吉非替尼的制备方法:中国, CN 104230823 A[P].2014-12-24 SHANG DB, LI NG. A Preparation Method of Gefitinib:China, CN 104230823 A[P].2014-12-24
[18] 李佳,张善军,高建. 一种吉非替尼Form 1晶型的制备方法:中国, CN 104277005 A[P]. 2015-01-14 LI J,ZHANG SJ,GAO J. A Preparation Method of Gefitinib Form 1: China, CN 104277005 A[P].2015-01-14
[19] 叶连宝,秦凌浩,胡巧红,等. 一种吉非替尼的精制方法:中国, CN104016930 A[P]. 2014-09-03 YE LB, QIN LH, HU QH, et al. A Refinement Method of Gefitinib: China, CN104016930 A[P].2014-09-03
[20] 钟俊,王国成. 一种吉非替尼Form 1晶型新的制备方法:中国, CN 103896862 A[P]. 2014-07-02 ZHONG J, WANG GC. A Novel Preparation Method of Gefitinib Form 1: China, CN 103896862 A[P].2014-07-02
[21] 李彦.ZD1839Form 1晶型的制备方法:中国, CN103102316 A[P]. 2013-05-15 LI Y. The Preparation Method of ZD1839 Form 1: China, CN103102316 A[P]. 2013-05-15
[22] 黎星术,张爱琴,黄玲. 一种吉非替尼的制备方法:中国, CN 102030716 B[P]. 2012-10-10 LI XS, ZHANG AQ, HUANG L. A Preparation Method of Gefitinib: China, CN 102030716 B[P]. 2012-10-10
[23] 叶建胜,黄常康. 一种Gefitinib Form 1晶型的制备方法:中国, CN 101973944 B[P]. 2012-07-04 YE JS, HUANG CK. The Preparation Method of Gefitinib Form 1: China, CN 101973944 B[P].2012-07-04
[24] 冷传新,李燕,林栋,等. 一种高纯度吉非替尼的制备方法:中国, CN 103012290 B[P]. 2015-05-13 LENG CX, LI Y, LIN D, et al. A Preparation Method of High-purity Gefitinib: China, CN 103012290 B[P]. 2015-05-13
[25] 何茂群,苗得足,王福生,等. 高纯度吉非替尼的制备工艺:中国, CN 102584720 A[P]. 2012-07-18 HE MQ, MIAO DZ, WANG FS, et al. The Preparation Process of High-purity Gefitinib: China, CN 102584720 A[P].2012-07-18
[26] 刘永东,车晓明,闵涛,等. 吉非替尼晶型I的精致方法:中国, CN 103360326 A[P]. 2013-10-23 LIU YD, CHE XM, MIN T, et al. The Refinement Method of Gefitinib Form I: China, CN 103360326 A[P].2013-10-23
[27] 丁克,李伟华,陆小云. 吉非替尼的制备方法:中国, CN 103570633 B[P]. 2015-08-05 DING K, LI WH, LU XY. The Preparation Method of Gefitinib: China, CN 103570633 B[P].2015-08-05

欢迎阅读《药物分析杂志》!您是该文第 1277位读者!

药物分析杂志 © 2009
地址:北京天坛西里2号
邮政编码:100050; 技术支持:010-60213898

电子邮件:ywfx@nicpbp.org.cn